Maarseveen, The Netherlands, 29 June 2018 – Today at the Dutch Biotech Event, Chrétien Herben, director of the LifeSciences@Work Accelerator, announced Hybridize as winning team of the 19th edition of the Venture Challenge. The LUMC-based start up Hybridize has developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BK virus-mediated damage while maintaining full immunosuppression.
Wouter Bos, bestuursvoorzitter van het VUmc en oud-minister van Financiën, wordt de eerste bestuursvoorzitter van Invest-NL, de staatsdeelneming die investeringen gaat stimuleren op maatschappelijke terreinen waar Nederland nu nog kansen laat liggen. Invest-NL zal naar verwachting in 2019 definitief worden opgericht en ondernemers dan één loket bieden voor risicokapitaal, garanties en financieringsprogramma's.
In preparation of the Microplastic & Health call for research proposals the concept call text went on-line for feedback. It was an open invitation for any stakeholders to participate. The aim of the consultation was to improve the quality of the call in terms of relevance to knowledge gaps and a way in which to adjust the call to the current state of scientific knowledge.
With a well-visited Health~Holland Pavilion and a strong delegation of 130 Dutch biotech entrepreneurs, this year’s BIO International Convention in Boston, Massachusetts, at the epicentre of biotech proved to be a fruitful edition for the Dutch too.
Een samenwerkingsproject waarin patiënten, onderzoekers en bedrijven helpen meerwaarde te halen uit het zelfonderzoek van patiënten naar de beste behandeling van hun chronische ziekte
Vandaag maakte NWO-voorzitter Stan Gielen bekend dat prof. dr. Anna Akhmanova, prof. dr. Marileen Dogterom, prof. dr. Carsten de Dreu en prof. dr. John van der Oost de NWO-Spinozapremie ontvangen, en prof. dr. Beatrice de Graaf en prof. dr. Marion Koopmans de NWO-Stevinpremie. De Spinoza- en de Stevinpremies zijn de hoogste onderscheidingen in de Nederlandse wetenschap. De laureaten krijgen elk 2,5 miljoen euro, te besteden aan wetenschappelijk onderzoek en activiteiten met betrekking tot kennisbenutting.
Oncode Institute has opened a call for applications for our Female Junior Investigator Programme (FJIP). Up to eight young female scientists will each be awarded € 150k,- per year during the first phase of Oncode, ending in 2022. The programme aims to support talented female junior investigators who have established their own line of research. Female scientists from all Dutch universities and research institutes can apply for funding.
One of the projects of InSciTe has been granted permission by the ‘Dutch Health and Youth Care Inspection’ (Inspectie Gezondheidszorg en Jeugd) to enter the clinical test phase. The Ocular Coil Drug Delivery Comfort Trial (OCDC) project developed an innovative way to apply medication to the eye. OCDC is the first public/private collaborative InSciTe project to reach this crucial phase within 3 years. This is an important achievement for the project partners and InSciTe.